Posted by Michael Wonder on 27 Nov 2018
Perrigo announces tentative FDA approval for the first to file generic version of Ultravate lotion 0.05%
26 November 2018 - Perrigo today announced it has received tentative approval from the U.S. FDA for the first to file generic version of Ultravate lotion (halobetasol propionate) 0.05%.
Perrigo previously announced a patent litigation suit with Sun Pharmaceutical Industries and MiCal Pharmaceuticals for this product.
Ultravate lotion, 0.05% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
